COST-EFFECTIVENESS OF FERRIC CARBOXYMALTOSE IN THE TREATMENT OF IRON-DEFICIENCY ANEMIA IN PREGNANT WOMEN

被引：0

作者：

Alves, Junior J. M. ^{[1
]}

Prota, F. E. ^{[1
]}

Martinelli, J. C. B. ^{[1
]}

Chrispim, A. ^{[1
]}

Christoforo, F. F. ^{[1
]}

Serpeloni, M. ^{[2
]}

Barreto, I ^{[3
]}

da Silva, A. C. ^{[3
]}

机构：

[1] Unimed Campinas, Campinas, Brazil

[2] Unimed Campinas, Nova Odessa, SP, Brazil

[3] Unimed Campinas, Campinas, SP, Brazil

来源：

VALUE IN HEALTH | 2024年 / 27卷 / 06期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EE256

引用

页码：S104 / S104

页数：1

共 50 条

[1] Ferric carboxymaltose for the treatment of iron-deficiency anemia
Munoz, Manuel
Martin-Montanez, Elisa
EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (06) : 907 - 921
[2] COST-EFFECTIVENESS OF FERRIC CARBOXYMALTOSE FOR TREATING IRON DEFICIENCY ANEMIA IN CHINA
Chuang, L. H.
Sun, W.
Serna, Ramirez de Arellano A.
VALUE IN HEALTH, 2022, 25 (07) : S406 - S406
[3] COST-MINIMIZATION ANALYSIS IN IRON-DEFICIENCY ANEMIA COMPARING INTRAVENOUS FERRIC CARBOXYMALTOSE TO STANDARD OF CARE IN PREGNANT WOMEN IN ALGERIA
AlAdham, L.
Benmouhoub, N.
Bradai, M.
Debbih, Dammene A.
Frigaa, I
Layaida, K.
Mahi, L.
VALUE IN HEALTH, 2022, 25 (12) : S311 - S311
[4] COST-EFFECTIVENESS OF FERRIC CARBOXYMALTOSE (FCM) IN THE TREATMENT OF IRON DEFICIENCY ANEMIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD)
Walter, E.
Lazic-Peric, A.
Schalle, K.
VALUE IN HEALTH, 2017, 20 (09) : A634 - A635
[5] COST-EFFECTIVENESS ANALYSIS OF FERRIC CARBOXYMALTOSE VERSUS IRON SUCROSE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN SPAIN
Arguelles, F.
Bermejo, F.
Borras Blasco, J.
Domenech, E.
Sicilia, B.
Huguet, J. M.
Serna, Ramirez de Arellano A.
Valentine, W.
Hunt, B.
VALUE IN HEALTH, 2022, 25 (01) : S95 - S95
[6] A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom
Pollock, Richard F.
Muduma, Gorden
JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (07) : 751 - 759
[7] Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain
Arguelles-Arias, Federico
Bermejo, Fernando
Borras-Blasco, Joaquin
Domenech, Eugeni
Sicilia, Beatriz
Huguet, Jose M.
de Arellano, Antonio Ramirez
Valentine, William J.
Hunt, Barnaby
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
[8] A PATIENT-LEVEL COST-EFFECTIVENESS ANALYSIS OF IRON ISOMALTOSIDE VERSUS FERRIC CARBOXYMALTOSE FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN THE UNITED KINGDOM
Pollock, R.
Muduma, G.
VALUE IN HEALTH, 2020, 23 : S373 - S373
[9] Ferric carboxymaltose for the treatment of iron-deficiency anemia (vol 13, pg 907, 2012)
Munoz, Manuel
EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (08) : 1219 - 1219
[10] Comparative effects of treatment with ferric carboxymaltose versus ferric derisomaltose in a murine model of iron-deficiency anemia
Rieg, Jessica Dominguez
Xue, Jianxiang
Thomas, Linto
Rieg, Timo
PHYSIOLOGY, 2023, 38

← 1 2 3 4 5 →